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Abstract: The development of a vaccine is necessary to combat the global hepatitis C virus 
(HCV) epidemic. The key to the development of a prophylactic vaccine is understanding the 
immune response in those who spontaneously resolve HCV infections versus those who develop 
chronic disease. Several promising vaccine candidates based on the use of viral vectors are cur-
rently in Phase I and Phase II clinical trials. The recently solved structures of the E2 glycoprotein 
have greatly aided epitope- and antibody-based vaccine design.
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Introduction
Approximately 185 million people or 2.5% of the world’s population are currently infected 
with hepatitis C virus (HCV), and there are 3–4 million new infections each year. A total 
of 60%–80% of infections will develop into chronic disease resulting in 350,000–500,000 
deaths annually due to HCV-related conditions.1,2 However, many more suffer with liver 
cirrhosis and approximately 3% will develop hepatocellular carcinoma.3
HCV is a blood-borne virus transmitted by exchange of bodily fluids. Therefore, 
it is most prevalent in certain populations: intravenous drug users, those receiving 
unscreened blood products, newborns, and those engaging in higher risk sexual 
activity.4–6 However, in approximately 10% of patients, the route of transmission is 
unclear.7
A complicating factor in the treatment of the disease is the genetic diversity of the 
virus, which has seven distinct genotypes and at least 30% genetic sequence variability. 
Genotype 1 is the most common in North America, Europe, and Asia, followed by 
genotype 3 and then genotype 2. Genotype 4 predominates in Africa and the Middle 
East but has recently spread to several European countries. Genotype 6 is less prevalent 
and is found mainly in South and East Asia. Genotypes 5 and 7 are rarer and account 
for ,1% of infections.8–10
Until recently, the standard of care for all genotypes was a combination therapy 
of pegylated interferon and ribavirin.11 Side effects are universal and include fatigue, 
fever, and nausea with additional psychiatric effects of insomnia, headaches, irrita-
bility, and depression.12 Since 2011, there has been a steady stream of direct-acting 
antivirals (DAAs) that have been licensed for treatment. These new drugs, which 
inhibit viral NS5B RNA polymerase, NS3 protease, or NS5A phosphoprotein, are 
used alone or in combination with the existing interferon treatment and have delivered 
significantly higher sustained viral response rates, improved genotype coverage, and 
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reduced treatment times.13,14 Side effects have been reduced, 
and interferon-free regimens are now possible.
Major downsides of the current therapies (including the 
DAAs) are side effects, high cost, and the late treatment of 
the disease, which commonly presents after years of chronic 
infection. Therefore, many patients already have irreversible 
liver damage and possibly liver cancer. Treatment rates are low, 
and, with an aging population, the incidence of cirrhosis and 
cancer is expected to triple by 2030 in developed countries.15 
Resistance to the DAAs may become an increasing problem.16 
Perhaps the largest barrier to treatment is the high cost. The 
older interferon treatment was expensive and already out of the 
reach of developing nations. Some less expensive treatments 
may become available to poorer nations when patents expire. 
However, the latest combination therapies may be beyond 
the reach of most countries, resulting in some controversy 
especially as production costs are relatively low.17
Despite ground-breaking improvements in treatment, the 
disease burden is set to increase both in poorer and in more 
affluent countries. Therefore, there is a pressing need for a 
prophylactic vaccine to provide protection from this disease 
and offer a potential route for eradication.
Virus structure and entry
HCV is a positive-strand RNA virus that belongs to the 
hepacivirus genus within the larger family of Flaviviridae 
that includes Dengue and Yellow fever viruses. The virus 
RNA genome is translated as a polyprotein that is cleaved 
to form three structural and seven nonstructural proteins 
(Figure 1A). The viral nucleocapsid assembles from the core 
protein and contains the viral RNA genome. The nucleo-
capsid itself is surrounded by the virus envelope that contains 
covalently linked complexes of the transmembrane proteins 
E1 and E2.18 The surfaces of E1 and E2 are highly glyco-
sylated containing 4 and 9–11 N-linked sites, respectively. 
E2 also contains four putative O-linked glycosylation sites 
(Figure 1B).19
The virus infects hepatocytes through a multistep process 
regulated by several intracellular signaling events.20 Virus 
particles are associated with lipoproteins, apolipoprotein E 
(ApoE), high-density lipoprotein, and low-density lipoprotein 
to form lipoviral particles. The entry process requires four 
essential receptors and coreceptors: scavenger receptor BI 
(SR-BI), CD81, and two tight junction proteins, claudin-1 and 
occludin. SR-BI is the first receptor to interact, initially with 
ApoE on the lipoviral particle and subsequently more directly 
with E2. The virus is taken into the cell via clathrin-mediated 
endocytosis and fuses with the endosomal membrane prior to 
uncoating and release of the viral genome.21 Until recently, E2 
was believed to be a class II fusion protein, similar to those of 
other flaviviruses, and to mediate this fusion event. However, 
recent crystal structure data showed that E2 does not adopt 
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Figure 1 HCV genome organization, polyprotein processing, and glycoprotein structure.
Notes: (A) The 9.6 kb positive sense RNA genome encodes a single ORF flanked by structured 5′ and 3′ UTRs. iReS-mediated translation yields a polyprotein precursor that 
is co- and posttranslationally processed to produce three structural and seven nonstructural proteins. (B) Schematic representation of the envelope glycoproteins e1 and 
e2. Numbers indicate amino acid positions in the HCV polyprotein of reference strain H, genotype 1a (GenBank accession no AF009606). N followed by a number indicates 
the position of N-linked glycans, shown as green trees. HVR-1 and HVR-2, the igVR, and the TMD are shown.
Abbreviations: HCV, hepatitis C virus; ORF, open reading frame; UTRs, untranslated regions; iReS, internal ribosome entry site; HVR-1, hypervariable region 1; HVR-2, 
hypervariable region 2; igVR, intergenotypic variable region; TMD, transmembrane domain; +ve, positive.
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the extended conformation of class II fusion proteins but has 
a compact, globular structure.22,23 The N terminus of E1 also 
has an unexpected fold and is unlikely to mediate class II 
fusion.24 The molecular detail of the roles of E1 and E2 in 
the fusion event is therefore unclear and will likely involve 
a novel entry mechanism.
Protective immune responses  
to HCV
Humoral responses
After initial infection by HCV, virus can be detected in serum 
after 1–3 weeks, but neither HCV-specific T-cells nor anti-
bodies are detectable for 1–2 months. This delay in adaptive 
responses may contribute to the chronicity of HCV.25–27 It 
is widely accepted that cellular responses can resolve acute 
infection but the role of neutralizing antibodies (nAbs) in this 
regard is less clear.28 Several studies have shown that indi-
viduals can clear HCV infection without an effective humoral 
response, showing that nAbs are not absolutely required. 
Nevertheless, nAbs appear to be important in the control of 
chronic infection and prevention of reinfection.26,29–33 In one 
example, depletion of serum antibody (Ab) resulted in higher 
viremia and worsening of the disease and restoration of Ab 
levels resulted in disease improvement.34
Recent work has provided stronger evidence for nAbs in the 
resolution of acute infection. The early generation of high-titer 
broadly neutralizing Ab (bnAb) is associated with clearance of 
acute infection, whereas the later appearance of low-titer nAb 
with limited cross-reactivity is found in chronic disease.33,35–38 
The role of Abs in protection from infection by HCV has 
also been demonstrated by passive immunization in animal 
models and in human beings.39–41 In human beings, this was 
observed in an incident involving a commercial intravenous 
immunoglobulin (IVIG) product prepared from pooled human 
plasma and used to treat primary immunodeficiency. After the 
introduction of screening by testing for HCV antibodies, one 
batch of the IVIG, from which units containing anti-HCV had 
been excluded, transmitted HCV to patients.42 The product 
was unfortunately contaminated with HCV, and the exclusion 
of plasma containing anti-HCV made it more infectious than 
earlier batches of IVIG made from unscreened plasma. Due 
to the protection provided by passive immunization, clinical 
trials are now proceeding to test the efficacy of HCV nAbs to 
prevent reinfection in liver transplant patients.43
Cellular responses
As with the humoral response, cellular responses to infection 
are delayed, and resolution of acute infection only occurs after 
the appearance of HCV-specific T-cells expressing IFN in the 
liver.44–47 The infection is met with a broad and strong helper 
T-cell (CD4+) and cytolytic T-cell (CD8+) response, which 
weakens and narrows in chronic disease.48,49 HCV-specific 
helper T-cells are difficult to detect in chronic disease, and 
the reason for their loss is poorly understood.50–52 CD8+ cells 
are also lost early in viral persistence, although this may 
be an adaptive response to prevent further tissue damage.53 
Pathways leading to the loss or exhaustion of HCV-specific 
CD8+ cells may involve several factors, including the loss of 
CD4+ cells, viral mutation and chronic antigen stimulation, 
and also the appearance of regulatory T-cells.28
The requirement for both CD4+ and CD8+ cells in the 
resolution of infection has been demonstrated in an animal 
model where chimpanzees that previously cleared the infec-
tion were reinfected after the removal of one subset or the 
other.54,55 Cytotoxic T-cell activity (T-cell perforin expres-
sion and hepatocyte apoptosis) can also be correlated with 
disease resolution in the chimpanzee model, implying a role 
for this cell type.56
In summary, spontaneous resolution of infection is asso-
ciated with an early adaptive immune response in the form 
of high-titer nAb and also a broad, strong, and sustained 
T-cell response where both helper and cytotoxic T-cells are 
absolutely required.
Vaccine approaches
Depending on race, age, genetics, and disease status, 20%–40% 
of individuals, after initial infection, eradicate the disease over 
a period of weeks or months.2,57 This has provided optimism 
that prophylactic vaccination to harness natural immunity 
could also be effective. Overall results using therapeutic vac-
cines have been disappointing, with only small reductions in 
viral loads, and therefore a prophylactic vaccine may be a more 
achievable target. A widely accepted goal of HCV treatment is 
the prevention of chronicity of infection, and this may be easier 
to achieve in uninfected subjects prophylactically than reverse 
it in infected patients with therapeutic vaccination. A confusing 
term in this regard is sterilizing immunity, which is commonly 
associated with prophylactic vaccination. Sterilizing immunity 
may be impossible to achieve with HCV, and more likely, 
a period of infection (or reinfection after future exposures) will 
precede viral clearance after prophylactic vaccination, similar 
to the scenario documented for patients who spontaneously 
resolve the disease.
So far, the development of a pan-genotypic vaccine to 
HCV has been challenging, mainly due to the genetic diver-
sity of the virus. However, a vaccine that protected against 
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a single common genotype would be a major advance. 
Another genetic problem for vaccine design is the high 
viral replication and mutation rate.58 The virus exists in the 
body as a constantly evolving quasispecies or vast swarm of 
closely related but distinct structures. This diversity presents 
particular problems for the humoral immune response and 
production of nAbs, which are the basis of all successful viral 
vaccines to date. HCV has also evolved a variety of strategies 
to evade antibody-mediated neutralization such as hypervari-
able regions (HVRs) within the envelope glycoproteins that 
act as immunological decoys (Table 1).28,59–68 How then can 
the immune system or a vaccine elicit a broadly neutralizing 
response to such an elusive target? One solution for vaccine 
development may be to focus on conserved epitopes. This 
strategy has also recently been adopted in vaccine design for 
human immunodeficiency virus (HIV) to overcome similar 
challenges of viral diversity and variability.69,70 Some rare 
bnAbs against HIV have been found after patient screening 
that are highly divergent from germline variable sequences, 
presumably having undergone extensive affinity maturation, 
and it has been suggested that novel vaccination strategies 
will be required to elicit them.71 This may also be the case 
for HCV, and one strategy that has been predicted to yield 
results is sequential vaccination with different but related 
antigens to more precisely direct the immune system.72 
Advances of in silico modeling will greatly aid the design of 
novel immunogens to mimic chosen epitopes.73 Additionally, 
next-generation sequencing means detailed analysis of the 
immune responses to vaccines is possible, and this will enable 
researchers to track the affinity maturation of particular B-cell 
linages that could elicit bnAb.
Prophylactic B-cell vaccines
Early vaccine research on HCV began exploiting the potential 
of the envelope glycoproteins E1 and E2. This approach pro-
duced some promising results in animal models.74 Substantial 
evidence of this approach comes from a meta-analysis 
of vaccine studies in chimpanzees, which concluded that 
structural proteins were better than nonstructural proteins at 
eliciting a protective response. This implies that nAbs are 
important to clear infection.75
Immunization of healthy volunteers with recombinant 
E1E2 heterodimer induced cross-reactive nAb responses 
to genotypes 1a, 1b, and 2a, but development of this vac-
cine is on hold because of the difficulty of producing intact 
recombinant heterodimer.76,77 The difficulty of producing 
recombinant protein can be overcome by heterologously 
expressing envelope glycoproteins in a viral vector or virus-
like particle (VLP).78 Although the whole molecule approach 
shows some promise, it may fail due to same viral evasion 
strategies that contribute to chronic infection (Table 1). An 
appropriately modified E2 protein, for example, without 
HVRs, may avoid viral evasion strategies and ultimately be 
a more successful candidate.79 However, folding issues may 
limit the use of singly expressed or modified E2 proteins.80 
Some recent research in chimpanzees failed to generate a 
nAb response using E2 lacking the HVR-1 region.81 The same 
work also demonstrated that only E1-vaccinated animals 
and not E2-vaccinated animals cleared HCV infection. In a 
Phase I clinical trial using a similar strategy, recombinant E1 
generated low-to-moderate Ab responses alongside a clear 
T-helper 1 response in nearly all participants.82
In summary, the use of whole glycoproteins can gener-
ate bnAb responses, although there have been mixed results 
using recombinant singly expressed E1 and E2.
Prophylactic T-cell vaccines
Most HCV vaccines have been designed as therapeutic strat-
egies and have focused on nonstructural epitopes to gener-
ate cellular (T-cell) responses. However, there are several 
promising prophylactic T-cell vaccine candidates that have 
progressed to clinical trials.83
One recent approach used adenoviral particles expressing 
the NS3–NS5 region of genotype 1b to generate long-lasting 
Table 1 Viral evasion strategies to avoid antibody-mediated neutralization
Viral evasion strategy Outcome References
Delay of the adaptive immune response Virus can establish infection 28
High genetic variability emergence of immune-escape mutants 59
Highly glycosylated envelope Antibody epitopes are shielded by glycans 60
Glycan shifting Alteration of local conformation abrogates nAb binding 61
Antibody interference nAb cannot bind to epitopes or neutralize virus 68
immunodominant hypervariable regions immune response targets non-neutralizing epitopes 62,63
Cell to cell transmission Virus hidden from antibodies 64
Viral particles associate with lipoproteins Antibody epitopes are shielded in lipoviral particles 65–67
Abbreviation: nAb, neutralizing antibody.
Vaccine: Development and Therapy 2015:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
35
Prophylactic vaccines for HCV
T-cell responses in healthy volunteers.84 This novel strategy 
used the adenoviral vectors human adenovirus 6 (Ad6) and 
chimpanzee adenovirus 3 (ChAd3), both containing DNA 
encoding the same region of the HCV genome. The immune 
system was primed with an initial inoculation of Ad6, and 
then boosted with several inoculations of ChAd3. These par-
ticular adenoviruses were chosen based on rare serotypes to 
reduce antivector immune responses, although such responses 
may have limited boosting in this study. The T-cell responses 
were predominately cytotoxic although helper T-cells were 
also present. T-cell responses were triggered by peptides from 
genotypes 1b, 1a, and to a lesser extent 3a, demonstrating 
a potentially wide treatment profile. Importantly, responses 
were also strong in a standard enzyme-linked immunospot 
(ELISPOT) assay measuring IFNγ (.1,000 SFC/106 periph-
eral blood mononuclear cells). A later study trial using ChAd3 
as the priming vector and modified vaccinia Ankara (MVA) 
as the boosting vector had arguably an even better T-cell 
response profile.85 As previously, long-term memory T-cells 
were present but also higher CD4+ cell levels and even higher 
CD8+ cell responses. This was possibly due to lower immune 
responses to the MVA virus particles used for boosting. In 
addition, the authors carried out a more in-depth study of 
T-cell subsets to show a vaccination profile similar to that seen 
in other successful viral vaccines or in natural immunity.86,87 
The next step is to discover if these responses are protective 
against infection. Phase I and Phase II trials to assess safety 
and efficacy are due for completion in 2016 (Table 2).88 The 
same strategy is also being tested in a Phase I/II trial as a 
therapy for HCV-infected patients, and it will be interesting 
to compare efficacy of these very promising viral vector 
stratagems.89 Two other viral vector vaccine strategies using 
Table 2 Current prophylactic vaccine candidates
Type of immune 
response targeteda
Sponsor Vaccine formulation Stage  
of development
Year Lead author References
Humoral (B-cell) Chiron/Novartis re1e2/MF59 Chimpanzee (n=7) 1994 QL Choo 74
Chiron/Novartis re1e2/MF59 Human being (n=60) 2010 Se Frey 76
Fujirebio europe re1/Alum (T2S-918/ 
innoVac-C)
Human beings (n=20) 2004 G Leroux-Roels 82
BPRC re1/Alum or re2/Alum Chimpanzee (n=4) 2011 Be Verstrepen 81
Cellular (T-cell) intercell AG iC41 (core, NS3, NS4  
peptides)/poly-l-arginine
Human being (n=60) 2008 CS Klade 93
intercell AG iC41 (core, NS3, NS4  
peptides)/poly-l-arginine
Human being (n=54) 2010 C Firbas 94
CSL Ltd/Novartis Core/iSCOMATRiX Human being (n=30) 2009 D Drane 95
Okairos Co Ad6/Ad24+ 
electroporated DNA
Chimpanzee (n=4) 2006 A Folgori 90
Okairos Co Ad6/ChAd32 Rhesus macaque (n=3) 2006 e Fattori 91
University of  
Oxford/Okairos Co
Ad6/ChAd3  
(NS3, NS4, NS5)
Human being (n=30) 2012 e Barnes 84
NiAiD ChAd3/MVA Human being (Phase i, 
n=68; Phase ii, n=382)
2016 No authors listed 88
NiH/Okairos Co Ad/DNA Chimpanzee (n=5) 2012 SH Park 92
Humoral and cellular 
(B- and T-cell)
Transgene DNA encoding e1, e2, and 
NS3 plus MVA encoding  
e1, e2, and NS3
Chimpanzee (n=4) 2007 CS Rollier 98
NiH VLP (core, e1, e2)/AS01B Chimpanzee (n=4) 2007 GA elmowalid 100
NYC Blood Center Recombinant vaccinia  
encoding e1, e2, P7, NS2, 
and NS3
Chimpanzee (n=4) 2008 JH Youn 99
Notes: aVaccines were classified as humoral (B-cell) if they contained recombinant E1, E2, E1–E2 heterodimer, or DNA encoding these proteins. Vaccines were classified as 
cellular (T-cell) if they did not contain recombinant e1, e2, e1/e2 heterodimer, or DNA encoding these proteins.
Abbreviations: Ad, adenovirus, numbers indicate type; ChAd, adenovirus of chimpanzee origin; BPRC, Biomedical Primate Research Centre, Holland; NiAiD, National 
institute of Allergy and infectious Disease, Bethesda, USA; NiH, National institute of Health, USA; DNA, Plasmids containing hepatitis C virus genetic material; n, number of 
subjects used in the study; rE1 or rE2, recombinant E1 or E2 protein; rE1E2, recombinant E1E2 heterodimer; VLP, virus-like particle; MVA, modified vaccinia Ankara; MF59, 
AS01B, iSCOMATRiX, proprietary adjuvants.
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adenoviruses are also currently being developed.90–92 In 
summary, the above vaccine strategies using viral vectors 
have great potential. However, formulating a vaccine with 
two different components may be expensive, and repeated 
boosting may not be practical in the developing world and 
for some patient groups.
Another vaccine candidate being developed for both 
prophylaxis and therapy uses synthetic peptides derived from 
the core, NS3, and NS4 proteins that have been chosen to 
stimulate both cytotoxic and helper T-cells.93,94 Participants 
for this modality of treatment will occasionally have to be 
human leukocyte antigen (HLA) matched to the peptides 
used for vaccination. HLA classes that bind to the peptides 
present in a vaccine can be predetermined experimentally 
and by computer analysis. This should generate optimal 
immune responses in selected patients for a particular set of 
peptides. Volunteers for this study were previously-treated 
HCV patients who possessed the HLA-A 0201 allele, which 
is present in 50% of Caucasians. The results from two clinical 
trials in healthy volunteers showed that response was corre-
lated with higher peptide doses and the use of adjuvants (poly 
l-arginine). However, the strength of the responses was very 
weak when compared to viral vector and VLP systems and 
there is no information on long-term memory responses. 
The company aims to develop this vaccine with a broader 
range of epitope targets and different adjuvants. This should 
help to increase the strength and breadth of T-cell responses 
achieved by this vaccine approach.
A third vaccine candidate designed to elicit protective cel-
lular responses against the core protein has also reached clini-
cal trials. This strategy involves injecting the core protein, 
expressed in yeast, with a novel proprietary adjuvant com-
posed of saponin, phospholipid, and cholesterol that forms 
spherical micelle-like structures. In a Phase I trial, nearly 
all participants developed antibodies to the core protein, but 
T-cell responses were only present in two volunteers (25%) 
receiving the highest dose of vaccine.95 These trial results 
were disappointing given previous promising results in a 
Rhesus macaque model.96 This approach, which is also being 
considered as a therapy for chronically infected patients, will 
have to achieve high T-cell responder rates. Further trials are 
planned with higher doses of vaccine.
Prophylactic B- and T-cell  
combined vaccines
For a successful outcome, B-cell vaccines that contain recom-
binant protein or peptide from E1 and/or E2 may have to be 
combined with a T-cell vaccine and heterologously expressed. 
This would increase the possibility of a strong, broad, and 
sustained humoral and cellular response.97 Another option is 
for the vaccine to contain both B- and T-cell epitopes. Three 
vaccines that contain both B- and T-cell HCV epitopes have 
been tested in the chimpanzee. Two are based on strains of 
vaccinia virus and a third on a VLP (Table 2).98–100
A prime and boost regimen using DNA and MVA encod-
ing E1E2 and NS3 has been developed. However, T-cell 
responses were transient and three of four animals were not 
protected from challenge with HCV.98
An HCV-based VLP vaccine encoding core, E1, and 
E2 has been developed by the National Institute of Health 
(USA). A high HCV-specific T-cell response was induced 
in four animals that were protected against subsequent 
challenge with a homologous strain.100 A lower dose to 
weight ratio in this study compared to previous mouse 
vaccinations may explain the lack of a humoral response. 
The high T-cell responses in this study show promise that 
this versatile vector may be developed into a successful 
vaccine approach.101
A lack of humoral response was also a characteristic of a 
vaccinia virus vaccine that encoded structural and nonstruc-
tural proteins.99 This vaccine, developed by the New York 
City Blood Center, induced a moderate T-cell response in 
four animals, and there was 100% protection from chronic 
disease after challenge with the same genotype. Some 
cross-genotypic protection was also found after combined 
challenge with six genotypes.
In summary, results from B- and T-cell combined vac-
cines have been mixed. In general, they have elicited good 
cellular responses and poor humoral responses.
New targets for future  
HCV vaccines
NAbs and key epitopes for vaccine design
Recent crystal structures of E2 peptides and of truncated E2 
protein complexed to bnAb have provided a starting point to 
design immunogens that elicit epitope-specific antibodies. 
Some bnAbs bind to conserved linear epitopes, and these are 
of great interest because technically it is to easier to make an 
immunogen that represents a linear rather than a discontinu-
ous epitope. However, nearly all the well-characterized bnAbs 
bind to discontinuous epitopes on E2 that are proposed to form 
part of the CD81 binding site.102 Extensive work has provided 
evidence for three main CD81 binding regions on the surface 
of E2 (regions 1–3 described later; Figure 2).68,103,104 BnAbs 
binding to these regions prevent E2 association with CD81 and 
presumably subsequent viral entry and fusion. Our understand-
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ing of the structure and location of neutralizing epitopes was 
greatly increased recently when two groups solved crystal 
structures of a truncated core of the extracellular domain of 
E2.22,23 The compact structure consists of a central β-sandwich 
flanked by front and back layers consisting of flexible loops 
and helices. To allow folding and crystallization, the N and 
C termini and also internal HVRs were omitted. Despite this, 
several areas of protein were disordered, including a key CD81 
binding region (region 1). It has been proposed that a nontrun-
cated E2, folded in the presence of E1, would adopt a slightly 
different structure with a different arrangement of disulfide 
bonds.105 Nevertheless, the structure shows that the proposed 
CD81 binding regions are juxtaposed on one face of the mol-
ecule (Figure 3). Notwithstanding these limitations, knowledge 
of the structure of E2 has rekindled interest in exploiting 
conserved neutralizing epitopes for vaccine design.
Key epitopes for vaccine design
Region 1
The region between residues 412 and 423, immediately 
downstream of HVR-1, contains some highly conserved 
amino acid (aa) residues that are recognized as a series of 
overlapping epitopes by a number of monoclonal antibodies 
(Figure 2).68 One such antibody is the mouse monoclonal 
AP33, which inhibits infection in cell culture models of HCV 
and neutralizes virus of all genotypes in HCV pseudoparticle 
(HCVpp) assays.106,107 A humanized, affinity-matured version 
of AP33 (MRCT10.v362) has an approximately threefold 
higher neutralization potency on three tested genotypes.61 
Therefore, this region is an exciting prospect for vaccine 
design.
The AP33 epitope has been characterized by ala-
nine-scanning mutagenesis and X-ray crystallography 
(Figure 3).61,107–110 The major determinants of antibody 
recognition are residues Leu 413, Asn 415, Gly 418, and 
Trp 420. The latter is a contact residue for all bnAbs that 
recognize this region and is critical for binding of E2 to 
CD81.61,104,107–112 The structures of three antibody–peptide 
complexes with bnAbs AP33, HCV1, and hu5B3.v3 show 
this region forming a β-hairpin structure.61,108–111 A fourth 
antibody–peptide complex of the same region with bnAb 
Figure 2 A linear map of the e2 envelope glycoprotein, showing regions recognized by nAbs and implicated in binding to CD81.
Notes: The sequences of individual bnAb epitopes are given below. Contact residues determined by structural analysis are highlighted in red. Dotted lines join two segments 
of a discontinuous epitope. The amino acid sequences and numbering are of reference strain H, genotype 1a (GenBank accession no AF009606).
Abbreviations: bnAb, broadly neutralizing antibody; HVR-1, hypervariable region-1; HVR-2, hypervariable region-2; igVR, intergenotypic variable region; TMD, 
transmembrane domain; nAb, neutralizing antibody; HCV, hepatitis C virus.
Figure 3 Core structure of HCV e2 glycoprotein ectodomain, showing regions that 
are recognized by neutralizing antibodies and implicated in binding to CD81.
Notes: Region 1 (aa 412–423) is shown in red, region 2 (aa 434–446) in blue, 
region 3 (aa 523–535) in green, and region 4 (aa 611–617) in purple. All four 
regions present large hydrophobic, aromatic amino acids (phenylalanine, tyrosine, 
and tryptophan) on one face of e2 that provide a hydrophobic interface for CD81 
binding. These residues all point or face toward each other in the structure, although 
conformational changes may alter their orientation. Region 1 is disordered in the 
crystal structure of e2 core, but a peptide representing this region forms a β-hairpin 
in complex with several antibodies. Here, the β-hairpin structure of region 1 (PDB 
iD: 4GAG) has been grafted onto the core e2 structure (PDB iD: 4MwF) using the 
UCSF Chimera program.140
Abbreviations: HCV, hepatitis C virus; aa, amino acid.
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3/11 shows the peptide adopting a very different, extended 
conformation.112 A fifth complex reveals a composite struc-
ture comprising a looser turn and extended conformation.110 
Therefore, it would appear that this region of E2 can adopt 
different conformations and is likely to be flexible. Indeed, 
this region is disordered in the crystal structure.23
Interestingly, this segment of E2 appears to have low 
antigenicity in HCV-infected patients and only 2.5% of 
patient sera tested positive to a peptide mimic.113 However, 
a vaccine based on this region could be much more antigenic 
and generate a stronger antibody response. Antibody-resistant 
mutants have been found by passaging HCV in the pres-
ence of bnAb AP33 in cell culture, which could indicate 
limitations of the protective effect of AP33-like antibodies 
in vivo.61,114 Encouragingly, another bnAb (HC-33) that is 
more resistant to immune escape has been isolated to this 
epitope.115 A combined immunogen based on the AP33 and 
HC-33 binding sites is an attractive prospect, as it raises the 
possibility of a vaccine that elicits a pan-genotypic bnAb 
response that is resistant to escape mutants.
Region 2
The region of E2 encompassed by aa residues 434–446 
(Figures 2 and 3) was previously thought to elicit mainly 
antibodies that inhibited neutralization by bnAbs specific for 
region 1.68 However, the recent discovery of bnAbs that bind 
to this region has shown that, although some interference 
between binding and neutralization to either region is pos-
sible, there can also be additive or synergistic neutralization 
when bnAbs to both regions are present.116 The structure of 
this region has been determined both in the context of E2 core 
and as antibody-bound peptides.23,117,118 It consists of a long 
N-terminal loop and a short C-terminal helix of 1.5 turns. 
However, the angle and local conformation of the loop and 
helix vary in different structures and this has been interpreted 
to mean that region 2 can adopt different conformations, 
which may reflect different functional binding states of E2.117 
Antibodies binding to this region can either be neutralizing or 
non-neutralizing depending on which conformation is bound. 
The short alpha helix contains the highly conserved aa resi-
dues Phe 442 and Tyr 443, which are implicated in binding 
to a hydrophobic pocket formed by the large extracellular 
loop on CD81.103,119,120 Phe 442 and Tyr 443 are also contact 
residues for several bnAbs, including HC-84.1, HC-84.27, 
and AR3C (Figure 2).23,118 The series of HC-84 antibodies 
that recognize this region have broad genotype specificity 
and some bind to linear epitopes.121 No immune-escape vari-
ants arose when the virus was passaged in the presence of 
the HC-84 series of bnAbs, showing that they are resistant 
to virus escape from neutralization.115 This region is another 
good target for an epitope-focused vaccine approach.
Region 3
This region, comprising aa residues 523–535, has been pro-
posed as a major binding site for CD81 that is also recognized 
by several bnAbs, some of which are effective across all the 
common genotypes (Figures 2 and 3).68,122,123 It includes the 
highly conserved residues Tyr 527, Trp 529, Gly 530, and Asp 
535 that have been identified by alanine-scanning mutagen-
esis as being critical for CD81 binding.104 Characterization 
of antibody recognition determinants using a variety of 
methods has provided evidence for contact with one or more 
of these highly conserved residues in a number of overlap-
ping epitopes.102 However, recent structural data conflict with 
some of the previous mutagenesis findings. The structure of 
the AR3C-E2 complex shows that the bnAb AR3C does not 
contact residues Gly 530 and Asp 535, as indicated previ-
ously by alanine scanning, and that its major binding site is 
region 2 and not region 3 as previously reported.23,124 This 
may also be the case for other bnAbs such as CBH-5 that 
are predicted, on the basis of alanine scanning, to share the 
same recognition residues.122 It is likely that mutagenesis 
in this region changes the conformation of E2 and prevents 
antibody recognition at other sites. The major contact residue 
in this region for AR3C based on the crystal structure data is 
Trp 529, which, together with other proposed CD81 binding 
residues, would contribute to a hydrophobic interface (Figure 
3). This segment of E2 appears to be relatively antigenic, and 
antibodies to it have been found in patient sera and in mice 
immunized with E2, although much of these data have been 
generated by alanine scanning and may not be reliable.124,125 
This region also appears to be resistant to the emergence of 
escape variants and would be another good prospect for an 
epitope-based vaccine, although some uncertainty exists in 
the residues involved in antibody and CD81 binding.126
Region 4
Early mutagenesis studies highlighted a small region between 
aa residues 611 and 617 as a potential CD81 binding site.127 
This finding has been supported by the characterization of the 
interaction sites of several bnAbs such as the HC-84 series 
and HC-11 (Figure 2).121 The tryptophan (W) present within 
this region (YPYRLWH) is a contact residue for some of 
the HC-84 series of bnAbs based on structural analysis and 
mutagenesis and could contribute to a hydrophobic interface 
for CD81 binding (Figure 3). This small segment of E2 is 
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recognized by conformational antibodies, and any peptide-
based vaccine would likely have to include other regions, 
described earlier, to allow antibody binding.
Other neutralizing epitopes
Two other regions have been described recently that are recog-
nized by bnAb and which are not part of the CD81 binding site. 
These areas, termed antigenic regions 4 and 5 by Giang et al, 
are formed in the heterodimer by clusters of residues in a rela-
tively unstudied part of E2 close to the membrane and perhaps 
also by residues in E1.123 The authors speculate that the epitopes 
are located at an interface between the two envelope proteins 
and are present only in the correctly folded E1E2 complex. 
Further characterization of these newly discovered epitopes is 
required to assess their prospects for vaccine design.
Future prospects
The potential of small conserved regions of E2 in a vaccine 
has been largely unexplored in human clinical studies. One 
approach could be immunization with peptides in combina-
tion with a suitable adjuvant. The peptide structure could 
be changed chemically, for example, by cyclization or pos-
sibly linked to a chemical or protein scaffold.128,129 Such 
changes of the natural structure could improve stability and 
antigenicity: a key issue with protein vaccination methods. 
A scaffold also offers the possibility of presenting multiple 
peptides in the correct orientation to mimic a discontinuous 
epitope in the native E2 structure. Such a strategy has been 
used to make a potential vaccine candidate for Respiratory 
Syncytial Virus.129 In this case computer modelling was 
used to design an immunogen that mimics the structure and 
orientation of an epitope bound by a well characterized nAb. 
A few animal studies have also used free peptides containing 
conserved epitopes of E2 to explore their potential to generate 
a humoral response. In one study, vaccination of mice with a 
T-cell helper epitope linked to peptide sequences generated 
nAb that inhibited entry of genotype 1a pseudoparticles into 
Huh-7 cells.130 In summary, the use of peptide antigens to 
mimic HCV structural epitopes has achieved mixed vaccina-
tion results. However, new technologies to improve stability, 
antigenicity, and orientation mean that they could still form 
part of a successful novel vaccination strategy. One approach 
would be to combine a peptide vaccine with another type of 
antigen such as a subunit vaccine with a prime and boost regi-
men to focus the immune system on particular epitopes.
The conserved epitopes could also be exploited using an 
anti-idiotype approach (Figure 4). In this strategy, a bnAb 
is used as the starting point to reverse-engineer a vaccine. 
By judicious screening, an antibody can be isolated whose 
variable regions mimic the shape of the original epitope. This 
antibody or a derived fragment of it is used as a vaccine. This 
novel vaccination approach has been used to treat cancer and 
is currently being developed for HCV.131–133
The epitopes could also be presented in a VLP or virus 
construct. This strategy has been used to express whole 
or truncated surface E1 and E2 in a vaccine context, but 
expression of the small conserved HCV epitopes in such 
constructs is unexplored. One platform that could be tested 
is a hepatitis B virus (HBV) VLP. Two different HBV 
VLPs are available, formed from either the core protein 
or the HBV surface antigen (HBVSAg). The HBV core 
protein that forms the capsid of the virus has proven to 
be a very flexible carrier of heterologous inserts. B- and 
T-cell epitopes have been inserted at the N and C termini 
as well as the major immunodominant region of the core 
protein in numerous vaccination experiments.134 Strong 
T-cell (helper and cytotoxic) responses are developed 
against the HBV core protein, and, given that cellular and 
humoral responses are both important in controlling HCV 
infection, the possibility of inserting HCV B- and T-cell 
Figure 4 Anti-idiotype vaccine approach.
Notes: A broadly neutralizing antibody (Ab1) is used as the starting point to 
reverse-engineer a vaccine that mimics the protective epitope. The Ab1 antibody is 
used to immunize mice. Sera from the mice are screened for antibodies (Ab2) that 
bind to the CDRs of Ab1. Some of these Ab2 antibodies may have a CDR region 
that mimics the shape of the original epitope. Such an Ab2 antibody can be used as a 
vaccine to elicit Ab3 antibodies that target the epitope and neutralize the virus.
Abbreviations: Ab, antibody; CDR, complementarity determining regions.
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epitopes into a HBV core protein is an intriguing one. The 
flexibility, high antigenicity, and compatibility with nearly 
any recombinant expression system make HBV core VLPs a 
very good candidate for an epitope-based vaccine for HCV. 
Although HBV core-based VLP vaccines have not pro-
gressed past the preclinical stage for HCV, two other HBV 
core-based vaccines have progressed to clinical testing for 
malaria and influenza A.135–137 Another possibility utilizing 
HBV is the insertion of HCV epitopes into the HBVSAg, 
which can also self-assemble with host lipids into VLPs 
without the nucleocapsid and is the basis of the successful 
worldwide HBV vaccine. In the field of HCV, this system 
has grounds for optimism as some recent work swapping 
the TM region of E1 and E2 with HBVSAg produced VLPs 
that induced high-titer nAb when used as a vaccine in an 
animal model.78,138 Many other VLP approaches using dif-
ferent platforms are also possible.101
A completely different approach would be the use of viral 
vectors. Viral vectors based on adenovirus or vaccinia could 
be used to express E2 epitopes in a standalone strategy or used 
in a prime-boost regimen when combined with E2 protein or 
peptides. A study in mice using Ad6 expressing full length 
and truncated E1E2 was combined in a prime and boost regi-
men with recombinant E1E2 protein to elicit strong cellular 
and bnAb responses. A similar approach using canary pox 
virus and the HIV surface protein gp120 has been the most 
successful HIV vaccine to date.139
Summary
Recent DAAs have revolutionized the therapeutic treatment 
of hepatitis C. However, the disease burden is still set to 
increase in developed and developing countries. A prophy-
lactic vaccine could circumvent treatment issues such as 
late diagnosis, high costs, and provide an eradication route 
for this disease.
Immune correlates of protection deciphered from study-
ing spontaneous resolvers and chronic patients have provided 
important clues to the potential attributes of a successful 
vaccine, although more work needs to be done to define 
this further.
The most advanced HCV vaccine to date involves the use 
of viral vectors with a prime and boost regimen. Notably, 
a similar strategy has led to the currently most successful 
HIV vaccine.
Recent crystal structures of the HCV envelope gly-
coprotein E2 have renewed interest in a rational vaccine 
approach to design immunogens that mimic conserved 
epitopes on E2.
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